COPD, Microbial Colonization, Respiratory Tract Disease
Conditions
Keywords
COPD, Gut microbiota, Respiratory tract, prebiotics
Brief summary
Some components of the diet could promote the growth of certain bacterial strains present in the intestine, which are closely associated with benefits for host health. An intestinal commensal Parabacteroides goldsteinii (Pg) was highlighted to be significantly negatively associated with severity of COPD. Furthermore, the investigators identify the potential prebiotics (PHGG) which may enrich the abundance of P. goldsteinii and increase the probiotic effect of P. goldsteinii. The investigators designed a randomized control study, which enroll adults diagnosed with COPD. Then the two groups will receive PHGG or not. Stool samples will be collected. The ameliorative efficacy will be evaluated by questionnaire and lung function test. Intestinal microbiota and metabolome will be analyzed and the correlation with lung function indices will be further investigated.
Detailed description
It is well known that some components of the diet could promote the growth of certain bacterial strains present in the intestine, which are closely associated with benefits for host health. In the previous study, the investigators found that an intestinal commensal Parabacteroides goldsteinii (Pg) was highlighted to be significantly negatively associated with severity of COPD. Furthermore, the investigators identify the potential prebiotics (PHGG) which may enrich the abundance of P. goldsteinii and increase the probiotic effect of P. goldsteinii. However, the effect of PHGG supplement on compositional and functional properties of the human microbiota with COPD still remains unclear. In this proposal, the investigators designed a randomized control study, which enroll adults diagnosed with COPD. The investigators will review their past medical records and related image and lung function test. Then the two groups will receive PHGG or not. Stool samples will be collected. The ameliorative efficacy will be evaluated by questionnaire and lung function test. Intestinal microbiota and metabolome will be analyzed and the correlation with lung function indices will be further investigated. In the future, it may be used to investigate and analyze the change of microbiota and metabolome, then develop possible treatment options of COPD.
Interventions
DIETARY_SUPPLEMENTPartially Hydrolyzed Guar Gum (PHGG)
Partially Hydrolyzed Guar Gum 5 gram/day for 1 month
Sponsors
Fu Jen Catholic University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
* age of 40-85 years * diagnosis of COPD made by pulmonologist * provision of written informed consent
Exclusion criteria
* severe and unstable comorbidities or active malignancy * COPD exacerbation within the 4 weeks prior * cognitive impairment or a psychiatric disorder * pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| blood cytokine | after PHGG 5 gram/day for 1 month | change of blood cytokine |
| Microbiota of stool | after PHGG 5 gram/day for 1 month | change of stool microbiota contribution |
| Modified Medical Research Council Dyspnea Scale (mMRC) | after PHGG 5 gram/day for 1 month | change of mMRC scale, 0 the best, 4 the worst |
| COPD Assessment Test (CAT) | after PHGG 5 gram/day for 1 month | change of CAT (0 the best, 40 the worst) |
| St. George's Respiratory Questionnaire (SGRQ) | after PHGG 5 gram/day for 1 month | change of SGRQ score, 0 the best, 100 the worst |
| FEV1 | after PHGG 5 gram/day for 1 month | change of FEV1 |
| FEV1% | after PHGG 5 gram/day for 1 month | change of FEV1% |
| FVC | after PHGG 5 gram/day for 1 month | change of FVC |
| FVC% | after PHGG 5 gram/day for 1 month | change of FVC% |
| FEV1/FVC% | after PHGG 5 gram/day for 1 month | change of FEV1/FVC% |
| FEV3 | after PHGG 5 gram/day for 1 month | change of FEV3 |
| FEV3% | after PHGG 5 gram/day for 1 month | change of FEV3% |
| FEV3/FVC% | after PHGG 5 gram/day for 1 month | change of FEV3/FVC% |
| MMEF | after PHGG 5 gram/day for 1 month | change of MMEF |
| MMEF% | after PHGG 5 gram/day for 1 month | change of MMEF% |
| PEF | after PHGG 5 gram/day for 1 month | change of PEF |
| PEF% | after PHGG 5 gram/day for 1 month | change of PEF% |
Countries
Taiwan
Contacts
Primary ContactYen-Liang Kuo, MD
Outcome results
None listed